Elixir Associates’ Post

🚀 Exciting Phase 3 Results for Dupixent in Chronic Urticaria! Sanofi and Regeneron have unveiled promising data from their phase 3 LIBERTY-CUPID C study, highlighting significant advancements for Dupixent in treating chronic spontaneous urticaria (CSU). 🧪 This could pave the way to offering a new lifeline to the 300,000+ Americans suffering from CSU who don't find relief with standard antihistamines. The study, involving 151 children and adults, showed that those treated with Dupixent and standard-of-care antihistamines experienced an impressive 8.6-point reduction in itch severity compared to a 6.1-point reduction with placebo. Additionally, 30% of Dupixent patients reported a complete response, a substantial improvement over the 18% in the placebo group. These results build on the success of the earlier LIBERTY-CUPID A trial and offer fresh hope for a population in need. Sanofi and Regeneron plan to submit their regulatory resubmission to the FDA by the end of the year. With Dupixent already widely used for conditions like atopic dermatitis and asthma, an approval for CSU would mark the first new treatment for this condition in over a decade. 🌟 #LifeSciences #ClinicalTrials #Dupixent #Regeneron #Sanofi